ACB Stock Analysis: Buy, Sell, or Hold?
ACB - Aurora Cannabis Inc. Common Shares
$4.06
-0.12 (-2.87%)
▼
HOLD
LOW Confidence
Last Updated: January 30, 2026
Earnings: Feb 04, 2026
2d
Smart Money Accumulation
ACB is down 8.4% this week, but smart money is accumulating calls. Top strike: $6 2026-03-20 with 2,939 OI. Call ratio: 60% View Scanner →
Strength: 5.2/10
Get Alerted When ACB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
3 traders called ACB this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ACB trades at premium valuation expecting 13.2% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: ACB trades at premium valuation expecting 13.2% growth. Hold existing positions but don't chase. Wait for better entry.
In-depth Analysis How we analyze
Valuation Analysis: ACB is currently trading at $4.06, which is considered oversold relative to its 30-day fair value range of $4.18 to $4.45. From a valuation perspective, the stock is trading at a premium (Forward PE: 58.0) compared to its historical average (40.0). At these levels, the market is pricing in 13.2% annual earnings growth.
Technical Outlook: Technically, ACB is in a downtrend. The price is currently testing key support at $4.03. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.41 (+57.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ACB is in a downtrend. The price is currently testing key support at $4.03. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.41 (+57.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$4.18 -
$4.45
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.9%
Protect Your Profits
Holding ACB? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 57.9% below Wall St target ($6.41)
- BULLISH: Expecting earnings turnaround to 13.2% growth with 11.4% revenue growth
- CAUTION: Recommendation downgraded due to -8.4% 5-day decline
Fair Price Analysis
30-Day Fair Range
$4.18 -
$4.45
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$4.03
Resistance Level
$4.49
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
58.00
Wall Street Target
$6.41
(+57.9%)
Revenue Growth (YoY)
11.4%
Earnings Growth (YoY)
-91.7%
Profit Margin
-15.6%
Valuation Premium vs History
+13.2% premium
PE vs Historical
58.0 vs 40.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+13.2%
(market-implied from PE analysis)
1-Year Target
$4.60
(+13%)
2-Year Target
$5.20
(+28%)
3-Year Target
$5.89
(+45%)
3-Yr Target (if PE normalizes)
(PE: 58→40)
PE COMPRESSION
$4.06
(0%)
Earnings growth offset by PE compression
Last updated: February 01, 2026 12:52 AM ET
Data refreshes hourly during market hours. Next update: 1:52 AM
Data refreshes hourly during market hours. Next update: 1:52 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Featured in Portfolios
ACB is a key holding in these high-performance investment strategies.
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$179 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$158 | 56 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$84 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 57 HOLD |
Advanced ACB Option Strategies
Professional options setups generated by AI based on today's ACB price and gamma walls.
